Abstract 54P
Background
The ovarian high-grade serous carcinoma (HGSC) lags in the exploitation of personalized biological therapies, while targeted inhibition of cancer driver events has improved the patient care in other solid tumor types. This ows to the copy-number driven HGSC pathogenesis, leading to few short driver mutations. We introduce a systematic multi-omic workflow to integrate evidence from genomic and transcriptomic data to identify credible, recurring, and targetable driver events.
Methods
The multi-omics workflow was piloted with data from 831 cancer samples of 290 patients with HGSC, enrolled to the ongoing prospective and longitudinal DECIDER study at the Turku University Hospital. We assembled short mutations, copy number changes, large indels, and translocations, and classified them as potential loss or gain of function. We evaluated the events by their heterogeneity and direct and downstream consequence on the RNA level, using prediction algorithms and databases as a support. The credible oncogenic events were overlayed with targets and biomarkers for cancer medicines listed in the Open targets and OncoKB databases, to identify promising treatment modalities for testing in patient-derived organoids.
Results
The most frequent oncogenic aberrations affecting the MAPK and PI3K patways included NF1 loss and AKT2 amplification, affecting 19% and 9% of cases, followed by PTK2 or KRAS amplifications or PTEN loss, each affecting about 5% of cases. At least one of these aberrations was detected in 47% cancers. The frequency of the aberrations varied by the cancer homologous recombination (HR) status, so that NF1 losses were enriched in HR-deficient cancers, but the AKT2 amplifications were detected almost exclusively in HR-proficient cancers. In a drug sensitization screen for carboplatin with different targeted inhibitors of the MAPK pathway, the pan-RAS inhibitor RMC-7977 was effective for a patient-derived organoid with NF1 loss.
Conclusions
We developed a systematic and comprehensive omics workflow for analysis of a copy number-driven cancer. We demonstrated the utility of the integrated genomic and transcriptomic analysis in identifying druggable driver aberrations and validated the predicted sensitivity in a patient-derived organoid.
Editorial acknowledgement
Clinical trial identification
NCT04846933.
Legal entity responsible for the study
University of Helsinki.
Funding
European Union.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Human adipose stem cells transfer their mitochondria to breast cancer patient derived organoids increasing drug resistance
Presenter: Martina Marigliano
Session: Cocktail & Poster Display session
Resources:
Abstract
175P - Differential impact of increased neoantigen load on PD-L1 positive immune cell infiltrations in comparison to PD-L1 expression on tumor cells
Presenter: Ashok Kumar Vaid
Session: Cocktail & Poster Display session
Resources:
Abstract
176P - Patient race is a determinant of the impact of Y chromosome loss on survival
Presenter: Suhyeon Choi
Session: Cocktail & Poster Display session
Resources:
Abstract
178P - Clinical correlates and impact of ctDNA levels on detecting distinct genomic alteration in patients with metastatic colorectal cancer
Presenter: Luca Boscolo Bielo
Session: Cocktail & Poster Display session
Resources:
Abstract
179P - Identification of guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer
Presenter: Deepa Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
180P - Unravelling drug resistance in high-grade serous ovarian cancer through clonal dynamics and single-cell heterogeneity analysis
Presenter: Alvaro Ingles Russo Garces
Session: Cocktail & Poster Display session
Resources:
Abstract
181P - Establishment of primary prostate cancer patient-derived organoids to assess PARP inhibitors antitumor activity beyond synthetic lethality
Presenter: Tatiana P. Grazioso
Session: Cocktail & Poster Display session
Resources:
Abstract
182P - METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation
Presenter: Maria Virginia Sanchez Becerra
Session: Cocktail & Poster Display session
Resources:
Abstract
183P - SomaVar: A web application for somatic variant storage, annotation and classification
Presenter: Sorin Armeanu-Ebinger
Session: Cocktail & Poster Display session
Resources:
Abstract